ncRNA basic information ncRNA ID: MI0003634 ncRNA Database: miRBase ncRNA Name: miR-620 ncRNA Type: miRNA ncRNA Expression: up-regulated ncRNA Method: RT-qPCR ncRNA Target Gene: DCTD ncRNA Pathway: NA Evidence (ncRNA-drug): validated

drug basic information Drug ID: DB00441 (APRD00201) Drug Name: Gemcitabine Drug Method: Between December 2011 and December 2014, 36 TNBC samples were obtained from Liaocheng Peoples Hospital. Three gemcitabine-resistant MDA-MB-231 cell lines (MDA-MB-231rGEM1, MDA-MB-231rGEM2 and MDA-MB-231rGEM3) were obtained by exposure of MDA-MB-231 cells to increasing concentrations of gemcitabine for >12 months. Reverse transcription-quantitative polymerase chain reaction was performed to detect the expression levels of specific genes, including microRNA (miR)-620, ATP-binding cassette sub-family B member 1 (ABCB1), ABCC10, cytidine monophosphate kinase, deoxycytidine monophosphate deaminase (DCTD), nucleoside diphosphate kinase 1 (NME1), ribonucleoside-diphosphate reductase large subunit (RRM1) and RRMB2. Western blot analysis was performed to assess the protein expression levels of DCTD. Furthermore, cell proliferation was assessed using a Cell Counting Kit-8 assay and cell apoptosis was detected using an Annexin V/Dead Cell Apoptosis kit. Interactions between miR-620 and DCTD were predicted using TargetScan and detected with the dual luciferase reporter assay. Drug Response: resistant

Cancer basic information Cancer: triple-receptor negative breast cancer Tissue/Cell: cell line(MDA-MB-231, BT549)

Other information Title: Overexpression of microRNA-620 facilitates the resistance of triple negative breast cancer cells to gemcitabine treatment by targeting DCTD. Journal: Exp Ther Med Published: 2019 PubMed ID: 31258693